Loading clinical trials...

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients With Advanced Solid Malignancies Including Malignant Lymphoma

NCT01588548•AstraZeneca

View on ClinicalTrials.gov

Summary

The purpose of this study is to investigate the safety and tolerability of AZD 1208 up to a maximum tolerated dose (MTD) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid malignancies including malignant lymphoma

Detailed Description

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients with Advanced Solid Malignancies including Malignant Lymphoma

Eligibility

Age

18 - 130 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who have signed this Written Informed Consent Form after a full explanation about the participation in this study
•Patients aged 18 years or older Patients diagnosed with a solid malignant tumour or malignant lymphoma that is refractory to standard therapies or for which no standard therapies exist
•Patients with good physical conditions (you can walk and can look after yourself) within the last 2 weeks.
•Patients who have at least one lesion that can be accurately assessed

Exclusion Criteria

•Patients who have recently received or are receiving prohibited medications or treatments
•Patients who have any unresolved side effects of previous treatments
•Patients who have spinal cord compression or brain metastases
•Patients who have severe systemic diseases (e.g., uncontrolled hypertension, hepatitis B, hepatitis C and human immunodeficiency virus \[HIV\] infection)
•Patients with significant abnormal ECG findings

Locations (3)

Research Site

Chūōku, Japan

Research Site

Manchester, United Kingdom

Research Site

Surrey, United Kingdom

Key Dates

Start Date

July 1, 2012

Primary Completion Date

July 1, 2014

Completion Date

July 1, 2014

Last Updated

November 4, 2015

Enrollment

ACTUAL participants

Conditions

Advanced Solid MalignanciesMalignant Lymphoma

Interventions

AZD1208

DRUG

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

NCT06756152

Biphenotypic Acute LeukemiaAcute Lymphoblastic Leukemia+4 more

View study

ACTIVE_NOT_RECRUITINGPHASE1

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

NCT06760481

Advanced Solid Malignancies

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 4, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Inclusion Criteria

Exclusion Criteria

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

EchoTip AcuCore Post-Market Clinical Study

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma